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Abstract
Hepatocellular carcinoma (HCC) is the most common primary
liver malignancy and the second leading cause of cancer-
related deceases worldwide. Early diagnosis is essential for
correct management and improvement of prognosis. Proposed
for the first time in 2011 and updated for the last time in 2017,
the Liver Imaging-Reporting and Data System (LI-RADS) is a
comprehensive system for standardized interpretation and
reporting of computed tomography (CT) and magnetic reso-
nance imaging (MRI) liver examinations, endorsed by the
American College of Radiology to achieve congruence with
HCC diagnostic criteria in at-risk populations. Understanding
its algorithm is fundamental to correctly apply LI-RADS in
clinical practice. In this pictorial review, we provide a guide for
beginners, explaining LI-RADS indications, describing major
and ancillary features and eventually elucidating the diagnostic
algorithm with the use of some clinical examples.
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Introduction
Responsible for approximatively 750,000 deaths worldwide,
hepatocellular carcinoma (HCC) is the most common primary
liver malignancy and the second leading cause of cancer-related
death.1 It is universally acknowledged that the etiology of
HCC is strictly related to cirrhosis, with almost 80% of HCC
cases arising in cirrhotic liver2 and with an annual incidence
ranging from 2% to 8%3 However, even if less frequently,
HCC can also develop in noncirrhotic livers, when affected by
chronic inflammation due to viral infections (especially linked
to hepatitis B virus (HBV) and hepatitis C virus (HCV)2,4 or
nonalcoholic steatohepatitis.5 Interestingly, the same environ-
ment also predisposes to the onset of intrahepatic cholangiocar-
cinoma (ICC),6,7 while it reduces the risk of liver metastases.8
The most important changes arising during HCC carcino-
genesis and the corresponding radiological signs are summar-
ized in Table 1.9,10 The prognosis of HCC is largely influenced
by the disease stage at the time of detection, as it has been
assessed that early-stage HCC can be managed with a number
of potentially curative treatments.11,12 Therefore, early diag-
nosis of HCC is critical to improve the survival of affected
patients.10 Recommended by both the European Association
for the Study of the Liver and the American Association for
the Study Liver Diseases, CTand MRI are currently recognized
as the most useful noninvasive tools for active surveillance of
HCC in at-risk populations.13–15
In the past, several clinical practice guidelines have been
suggested by organizations all over the world, in the attempt to
standardize imaging-based criteria for HCC diagnosis.16
Nevertheless, these guidelines have some limitations, such
as the inconsistency between different systems in definition
of pathological features, the extent of the indeterminate cate-
gory and the lack of indications for differential diagnosis from
other malignancies or for characterization of macrovascular
invasion.17,18 Proposed for the first time in 2011 and then
updated in 2013, 2014 and 2017, the Liver Imaging-Reporting
and Data System (LI-RADS) is a comprehensive system for
standardized interpretation and reporting of CT and MR liver
examinations, endorsed by the American College of Radiology
to overcome the mentioned limits and achieve congruence
with HCC diagnostic criteria in at-risk populations.17,18
Describing some major and ancillary imaging features to
apply through a precise algorithm, LI-RADS classifies CT or
MRI observations into five categories, from LR-1 to LR-5,
corresponding to a crescent probability of HCC, where LR-1
and LR-5 represent respectively the 0% and 100% probability
of HCC (Table 2).19,20 Thus, the system provides three labels
(LR-2, LR-3 and LR-4) to differentiate uncertain observations,
responding to the need of narrowing the broad indeterminate
category, that used to result from the dichotomic approach of
“definite versus nondefinite HCC”.18 Importantly, LI-RADS
defines a further category of LR-TIV (LR-tumor in vein) for
lesions associated with macrovascular invasion, moving
towards the TNM staging system, which requires the delinea-
tion of the vascular involvement to plan the treatment strat-
egy.18,20 Moreover, malignancies other than HCC can be
classified under the label LR-M using LI-RADS-specific guide-
lines for differential diagnosis.20 Eventually, LI-RADS provides
a structured reporting template, recommendations on optimal
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imaging protocol, management suggestions and, in the last
update (v2017), criteria for CT/MRI treatment response
assessment.20
In this pictorial review, we aim to explain the LI-RADS
algorithm, summarizing the major and ancillary features, in
order to supply an educational guide for practical use for CT
and MRI diagnosis of HCC.
Indications
LI-RADS provides a CT/MRI diagnostic algorithm that can be
applied only in a high-risk population for HCC.20 Namely, the
last version defines as high-risk patients those affected by cir-
rhosis, chronic hepatitis B without cirrhosis or by a prior HCC,
including adult liver transplant candidates and recipients post-
transplantation.20 Conversely, LI-RADS cannot be used in the
absence of the above risk factors or in a pediatric population,
even when affected by cirrhosis due to congenital hepatic fib-
rosis, since its use has not been validated for patients less than
18-years-old.19
Interestingly, LI-RADS excludes patients with cirrhosis due
to vascular disorders, such as hereditary hemorrhagic telan-
giectasia, Budd-Chiari syndrome, chronic portal vein occlusion,
cardiac congestion, or diffuse nodular regenerative hyper-
plasia,20 since these conditions represent an environment pre-
disposing to the development of benign arterialized nodules
that may mimic HCC, leading to misdiagnosis.19 Furthermore,
LI-RADS v2017 recommends application of the algorithm only
for multiphase imaging examinations either performed with CT
or MRI and with extracellular contrast agents (ECAs) or MRI
with hepatobiliary contrast agents (HBAs).20 Contrarily, single-
phase or double-phase CT-MRI cannot be considered adequate
for the employ of LI-RADS algorithm.20
Eventually, LI-RADS algorithm should be proscribed for
observations that are path-proven malignancies or path-
proven benign lesions of nonhepatocellular origin, such as
hemangiomas.
Major and ancillary features
LI-RADS defines criteria that should be used to classify a liver
observation. Here, the term “observation” refers to a focal area
with imaging features that differ from those of adjacent liver
parenchyma, and replaces the terms “lesion” or “nodule” since
it also includes “pseudolesions”, such as artifacts or perfusion
alterations.18 The imaging features selected by LI-RADS are
divided into two main groups, according to their role in the
diagnostic algorithm: the major and ancillary features.20
Major features
LI-RADS provides four major features—arterial phase hyper-
enhancement (APHE), wash-out (WO) appearance, capsule
appearance, and threshold growth. These features are valid
both for CT and MRI, since they can be detected by any
dynamic contrast-enhanced examination and performed with
administration of either extracellular or hepatospecific contrast
agents, providing that it includes three dynamic phases: the
arterial, portal and delayed phase.20 Although the individual
features are nonspecific, the combination of them is highly
specific for HCC in at-risk populations,21–23 reaching approxi-
mately 100% specificity for 10–19 mm observations featured
by visibility as a distinctive nodule at former surveillance ultra-
sound, APHE and WO appearance.9,21 The main limitation of
employment of major features for diagnosis and staging of
HCC is the low per-lesion sensitivity, since most (e.g., the
APHE and the capsule appearance) are typical of progressed
HCC and barely useful in early HCC detection.9,10
APHE
LI-RADS defines APHE as a nonrim-like enhancement in the
arterial phase that is unequivocally greater in attenuation or
intensity in whole or in part than the liver (Figs. 1A and 2A,
2C).20 It must be noticed that the expression “arterial phase”
refers to the “hepatic arterial phase”, which is featured by
Table 2. LI-RADS diagnostic categories (on the left) and examples of LR-1 and LR-2 entities (on the right). From the American College of Radiology - Liver
imaging reporting and data system version (LI-RADS®) v2017
LR-NC
LR-1
LR-2
LR-3
LR-4
LR-5
LR-M
LR-TIV
Diagnostic
categories
Probably or definitely
malignant, not
necessarily HCC
Not categorizable
(due to image omission
or degradation)
Definitely benign
Probably benign
Intermediate probability
of malignancy
Probably HCC
Definitely HCC
Tumor in vein
LR-1
LR-2
Definite:
• Cyst
• Hemangioma
• Perfusion alteration (e.g. arterioportal shunt)
• Hepatic fat deposition/sparing
• Hyertrophic pseudomass
• Confluent fibrosis or focal scar
Spontaneous disappearance
List above not meant to be exhaustive
Probable:
Distinctive nodule without malignant imaging features
List above not meant to be exhaustive
• Cyst
• Hemangioma
• Perfusion alteration (e.g. arterioportal shunt)
• Hepatic fat deposition/sparing
• Hyertrophic pseudomass
• Confluent fibrosis or focal scar
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simultaneous full enhancement of the hepatic artery and
branches and by the absence of hepatic vein enhancement.20
Moreover, LI-RADS distinguishes two subtypes—the early and
the late arterial phase, respectively characterized by the
absence or the presence of portal vein enhancement, with rec-
ommended use of the latter since APHE is often stronger or
even detectable only in this phase.20 Also called “wash-in” or
“arterial hypervascularity”, APHE is a dynamic profile corre-
lated to neoangiogenesis with formation of impaired arteries
that occurs late during hepatocarcinogenesis.10,24
Being a distinctive feature of progressed HCC, APHE has a
prominent role in the LI-RADS algorithm.18,20 However, APHE
is not completely specific, since it can also be observed in
benign perfusion alterations, small hemangiomas, small focal
nodular hyperplasia–like lesions,25,26 in some atypical cases of
focal or confluent fibrosis and in some atypical cirrhotic and
dysplastic nodules or small hypervascular metastases such
as neuroendocrine tumors.9,16 In addition, in patients with cir-
rhosis or chronic hepatitis, small vascular pseudolesions attrib-
utable to arteroportal shunts are particularly common, and the
large majority of focal areas of enhancement seen only in the
arterial phase and measuring <2 cm are nonneoplastic,27
especially those that are wedge-shaped and subcapsular.28
Furthermore, APHE sensitivity decreases with the diameter of
the observations, dropping from 100% to 32% for observa-
tions, respectively, for sizes of >20 mm and <10 mm, even
using MRI.29
WO appearance
WO appearance is defined as a nonperipheral, visually-
assessed, temporal reduction in enhancement in whole or
in part compared to the surrounding liver parenchyma from
the earlier to later phase, resulting in hypoenhancement in
the extracellular phase (Figs. 1B, 2B, 2D and 3B).20 Since
this pattern can be more conspicuous or even depictable
only in the delayed phase,30,31 the LI-RADS recommends
to state WO appearance evaluating of both portal venous
and delayed phases when administrating ECAs or gaboben-
ate.20 Conversely, in case of employment of gadodexate,
only portal venous phase should be considered and any
hypointensity in the transitional phase (which is not a real
delayed phase) should be reported as an ancillary feature
and not as a WO appearance.20
Importantly, LI-RADS advocates the expression “WO
appearance” instead of the simple WO, since the mechanisms
underlying this pattern in HCC are not fully understood.
Indeed, several concurrent factors have been hypothesized,
such as early venous drainage of contrast material from the
tumor, progressive enhancement of background liver, reduced
intranodular portal venous blood supply, tumoral hypercellu-
larity, and intrinsic hypoattenuation/hypointensity.32 Like
APHE, WO appearance by itself is not specific for HCC, as this
feature may be observed in cirrhotic and dysplastic nodules, in
metastasis and in hepatocellular adenoma, even if the last two
conditions are both rare in the HCC at-risk population.8,10,33
Fig. 1. LI-RADS algorithm for application of major criteria (on the top). From the American College of Radiology - Liver imaging reporting and data system version
(LI-RADS®) v2017. Observation in a 49-year-old man with HCV-related cirrhosis (on the bottom). The magnetic resonance images demonstrate a 48 mm observation with
APHE (A) and both wash-out out and enhancing capsule in portal venous phase (B), meeting the criteria (APHE + size > 2cm + 2 major features) for LR-5. Note the in-
homogeneous structure of the observation reflecting a “mosaic” architecture.
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Additionally, focal areas of parenchymal distortion and
enhancing fibrosis may create a perception of WO, named
“pseudoWO”.34
Enhancing “capsule”
LI-RADS defines an enhancing “capsule” as a smooth, homo-
genous, sharp border surrounding entirely or partly an obser-
vation, unequivocally thicker or more conspicuous than fibrotic
tissue around neighboring cirrhotic nodules and visible as a
rim featured by progressive enhancement from early to later
phases (Fig. 1B).20 This characteristic dynamic pattern has
been attributed to slow flow within intracapsular vessels,
as well as contrast agent retention within the extravascular
connective tissue of the capsule.35 Nevertheless, it should
remarked that LI-RADS reports the term “capsule” with quota-
tion marks, since the rim of enhancement does not necessarily
correlate with the presence of a true tumor capsule at pathol-
ogy19 but it may represent a pseudocapsule corresponding to
fibrous tissue and dilated sinusoids around a nodule.36 In
both cases, the enhancing “capsule” is a specific feature of
progressed HCC,23,34–37 since it is normally absent in pre-
cursor nodules (cirrhotic nodules and dysplastic nodules)
and nonHCC tumors.23,34,37
Indeed, this major feature has shown itself to be an
important predictor of HCC, permitting definitive diagnosis of
HCC when associated with APHE and an observation size of
2 cm or larger, regardless of the presence of WO appear-
ance.34,38 A potential pitfall in applying this feature is that some
small ICCs show peripheral enhancement in all phases,39 which
may be misinterpreted as a “capsule”; a discriminating charac-
teristic is that the peripheral enhancement in ICC tends to
peak in the arterial phase and diminish in later phases, rather
than progress. Another possible snare is that fibrous tissue
surrounding cirrhotic nodules and dysplastic nodules may
enhance on delayed phase images, generating the perception
of a “capsule”.34 Thus, LI-RADS specifies the term “unequivo-
cally” in the definition of the enhancing “capsule”, in order to
prevent an inappropriate application of this feature.20
Moreover, importantly, LI-RADS v2017 adds the adjective
“enhancing” to “capsule” in the algorithm table as well, to
highlight the distinction from “nonenhancing capsule”, which
is a peripheral rim visible in other MRI sequences such as T2-
weighted or the hepatobiliary phase (HBP) that should be
considered just as an ancillary feature favoring HCC.20
Threshold growth
The definition of HCC growth is an object of debate because
growth has been variably defined in the various studies that
have contributed to consensus criteria.18 LI-RADS defines
growth as an unequivocal increase in the diameter of an obser-
vation, measured on examinations performed on different
dates, which is not attributable to artifact, differences in tech-
nique between the two examinations, or measurement error.20
Growth can be considered as a major feature of HCC whenever
it achieves a threshold defined as an increase in maximum
diameter of at least 50% within 6 months or at least 100%
Fig. 2. Particular cases of LR-5 on MRI. (A, B) 14-mm observation in a 73-year-old woman with chronic hepatitis B, previously treated for HCC. (A) Arterial phase
demonstrating APHE (arrow). (B) Portal venous phase demonstrating “wash-out” (arrow) and no enhancing capsule or threshold growth. Since the observation has APHE,
10<d<20 mm and one major feature, the final category is LR-4/5. The nodule was reclassified the same day as a LR-5us, as it was visible at ultrasound examination. The
hypointense triangular area (arrowhead) has to be correlated to previous treatments. (C, D) 48-mm nodule (arrow) in a 73-old-woman with hepatitis C cirrhosis. (C) Arterial
phase demonstrating a focal APHE in a bigger surrounding nodule (arrow). (D) Portal venous phase showing “wash-out”. Thus, the observation is featured APHE +size >2 cm
plus one major feature. The final category is LR-5. Note, in this case the focal APHE is inside a larger nonenhancing nodule, reflecting the “nodule-in-nodule” architecture.
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diameter increase per year.20 Despite HCC growth rate
varies widely, secondarily to the size or histologic grade of
the tumors, LI-RADS decided to fix a threshold in order to
decrease the likelihood of a false-positive diagnosis caused
by slow-growing benign entities, including some dysplastic
nodules.18
Interestingly, new lesions measuring at least 1 cm are also
given credit for threshold growth if they were not visible at a CT
or MRI that had been performed less than 1 year before.16,20
A diameter increase of less than the threshold growth is an
ancillary feature that favors HCC.18,20 In this case, LI-RADS
does not stipulate a minimum increase in diameter required
for use as an ancillary feature.20 Since it is a major criterion
for the diagnosis of HCC, radiologists should exercise judgment
in the application of the threshold growth feature, which refers
only to an unequivocal increase in the diameter of an observa-
tion.18,20 Moreover, diameter increase should be assessed on
images in the same plane and, if possible, acquired in the same
phase or sequence.20
Because the difficulty in differentiating nodules from sur-
rounding peritumoral enhancement can lead to overestimation
of tumor size, LI-RADS recommends measurement on phases
that are relatively constant over time (e.g., venous or pre-
contrast phases).20
Ancillary features
Although their presence is an accurate positive indicator of
HCC, major features were found to underestimate its occur-
rence by 40–60% of cases according to the size of the
Fig. 3. LI-RADS algorithm for application of ancillary criteria (on the top). From the American College of Radiology - Liver imaging reporting and data system version
(LI-RADS®) v2017. Magnetic resonance images showing a 15-mm nodule (arrow) in a 77-year-old man with hepatitis C-related cirrhosis (on the bottom). (A) Arterial phase
does not demonstrate a clear APHE. (B) Portal venous phase shows “wash-out”, a major feature for HCC. Since the observation has no APHE, it is <20 mm and has only one
major feature favoring HCC, it was initially classified as LR-3 according to the left part of the table algorithm. However, the observation was hypointense in the hepatobiliary
phase (C) and slightly hyperintense in T2W images (D). So, using these two ancillary features favoring malignancy, we could upgrade the LI-RADS score to the final category
of LR-4, probably a HCC. The patient underwent a biopsy which confirmed the diagnosis.
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lesion.14,34,40 Therefore, in addition to these standard diag-
nosis methods, others have been investigated that may be
employed for enhanced accuracy.17,41 LI-RADS defines these
additional signs as “ancillary features”, classifying them into
two groups. The first group comprises those signs favoring
malignancy, but which are not specific of HCC. The second
group includes those markers that characterize HCC espe-
cially.20 The list of all LI-RADS ancillary features is reported
in Table 3.20
Below, we discuss some of the main ancillary features
favoring malignancy and HCC in particular.
Ancillary features favoring malignancy, but not HCC in
particular
HBP hypointensity
Hepatocellular adenomas (HCAs) are paramagnetic gadolinium
chelates, determining shortening of the T1 relaxation time,
that, compared to conventional extracellular gadolinium-based
contrast agents, are able to provide similar arterial and portal
venous phases, but because of their hepatocyte specific uptake
they also enable an HBP.42,43 Gadobenate dimeglumine and
gadoxetic acid are the two liver-specific MRI contrast agents
used in clinical practice.9 After the dynamic phase, a specific
transporter receptor called the organic anion transporter
(OATP), which is part of the biliary transport system, carries
these agents into hepatocytes. Later, the agents are excreted
into bile canaliculi via the multidrug resistance-associated
protein (also known as the canalicular multispecific organic
anion transporter; cMOAT).44
Robust evidence have shown that OATP expression
declines during hepatocarcinogenesis, so the evaluation of
signal intensity in the hepatobiliary phase can help to identify
and characterize hepatocellular nodules in the cirrhotic
liver.9 Moreover, hepatobiliary agents permit the assessment
of hepatocellular function as well, based on signal intensity of
the liver in the HBP, which tends to drop in patients with
impaired liver function.9
Ideally, 50% of the injected dose of gadoxetate disodium
is eliminated in the bile, with a peak of parenchymal
enhancement that occurs at approximately 20 min after
the injection of the contrast media so that a 20-min delay
acquisition usually results in an adequate HBP.45 Gadobenate
dimeglumine has lower biliary excretion (2;4%), so an
adequate HBP can be reached usually in 1 h in normal
patients, but a delay of 1–3 h is necessary in patients with
impaired liver function or a severe cirrhosis.45 LI-RADS
defines the HBP hypointensity as an intensity in the HBP
that is unequivocally less, in whole or in part, than liver.20
This feature constitutes a very sensitive sign, since it can be
seen in 79–99% of HCCs,46 including well-differentiated early
HCCs (Fig. 3C).47
What pathological data suggest is that, in cirrhotic liver,
OATP expression is still preserved in dysplastic nodules
(which in HBP typically have similar signal intensity to
surrounding liver parenchyma); it starts to decline just after
malignant transformation, before the arterialization of the
nodule is realized.9,10 This a key point, because it means that
HBP hypointensity allows the detection of HCC, even before
the onset of APHE.9,10 Given that approximately 20–40% of
lesions smaller than 20 mm in diameter do not show a clear
enhancement in the arterial phase, the HBP represents an
essential tool to increase MRI diagnostic accuracy, allowing
for differential diagnosis between HCC and dysplastic
nodules, even when conventional imaging fails.48
Moreover, HBP hypointensity can help to differentiate
between hypervascular small HCCs and arteriovenous shunts
or focal nodular hyperplasia (FNH)-like lesions, since such
observations remain iso- or hyperintense in HBP, in contrast
to HCC.48 Despite HBP hypointensity is a reliable predictor of
HCC in at-risk populations,42 it lacks specificity since it can also
be observed in some atypical dysplastic nodules, in all other
liver malignancies (metastases included) and in some benign
entities like hemangiomas.49 Furthermore, radiologists should
be aware that almost 10% of well-differentiated HCC show
HBP hyperintensity, instead of the expected hypointensity.10
This potential pitfall relates to the fact that the dedifferentia-
tion process can sometimes lead to overexpression of OATP-
8, even if this possibility is definitely less frequent than the
underexpression.9
Mild-moderate T2 hyperintensity
Mild-moderate T2 hyperintensity is defined as an intensity on
T2-weighted images that is mildly or moderately higher than
liver and similar to or less than noniron-overloaded spleen,20
but also less than bile ducts or other simple fluid-filled
Table 3. List of LI-RADS ancillary features
Ancillary features favoring malignancy
Ancillary features favoring
benignity
Ancillary features favoring
malignancy malignancy in general
Ancillary features
favoring HCC
Mild-moderate T2 hyperintensity Corona enhancement Homogenous marked T2 hyperintensity
Restricted diffusion Mosaic architecture Homogeneous marked T2
or T2* hypointensity
Lesional fat sparing Nodule-in-nodule architecture Undistorted vessels
Lesional iron sparing Intralesional fat Parallels blood pool enhancement
Blood products Non enhancing capsule Diameter reduction
Diameter increase less than threshold growth Diameter stability 2 years or more
Hepatobiliary-phase hypointensity Hepatobiliary-phase isointensity
Transitional phase hypointensity
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structures (Figs. 3D and 4).9 The biological basis for this
feature is not well-understood.
Some authors have suggested that hyperintensity on
T2-weighted imaging is consistent with the alterations of
vascular profile occurring during hepatocarcinogenesis, such
as sinusoid dilation50 or increased intratumoral arterial supply
corresponding to decreased intratumoral portal blood supply.47
However, it is still not clear whether it’s the blood itself (blood
volume or blood flow amount) that directly influences the signal
intensity or if it depends on other factors which are yet to be
determined.51 Some other data have correlated hyperintensity
of HCC on T2-weighted images with the dedifferentiation of
hepatocellular nodules, since progressed HCCs often result in
T2 hyperintensity,52 even if APHE is not present.9 Indeed, it has
been supposed that T2 elongation in HCC nodules reflects
the morphological changes along hepatocarcinogenesis, from
trabecular to solid growth pattern, regardless of the presence
of vascularity alterations53 that may occur late.54
Usually, in T2-weighted imaging, regenerative nodules are
indistinct, dysplastic nodules, appearing as iso- or hypointense,
whereas early HCC is typically isointense or mildly hyper-
intense.9 So, any T2 elongation in at-risk patients should be
considered as highly suggestive of a malignancy.55 Evidence
have shown that T2-weighted imaging is particularly valuable
together with diffusion-weighted imaging (DWI) for differenti-
ating between small atypical HCCs (<3 cm) and dysplastic
nodules,56 as the presence of mild-moderate T2 hyperintensity
or restricted diffusion strongly favors the diagnosis of a malig-
nant nodule in cirrhotic patients, even if the typical feature of
the arterial hyperenhancement is still missing.10
Recently, a consensus report statement confirmed the
importance of mild-moderate T2 hyperintensity, recommend-
ing its use in the diagnosis and staging of HCC.57 However,
since mild-moderate T2 hyperintensity can be frequently
observed in ICCs and liver metastases as well,9 the LI-RADS
endorses its application, but only as an ancillary feature
favoring generic malignancy and not specifically HCC.20
Restricted diffusion
DWI is an MRI spin-echo planar imaging sequence, sensitized
to the driven random motion of water molecules (water
diffusion) by the application of gradient pulses, the entity of
which is indicated by a factor known as the b-value; the higher
the b-value, the more sensitive the sequence is to water
diffusion.58 The subset of DWI is the simple assumption that
water diffusion in the extracellular compartment is influenced
by the cell membranes and macromolecules,59 resulting in dif-
fusion restriction whenever cellularity increases, reducing the
width of interstitial spaces.58 Importantly, water diffusion can
be quantified by a mathematical index called the apparent dif-
fusion coefficient (ADC); low ADC values mean restricted dif-
fusion, namely hypercellularity that impedes the mobility of
water molecules.58
LI-RADS allows the use of restricted diffusion, as an ancillary
promalignancy feature, when the observation presents an
intensity on DWI that is not attributable exclusively to T2
shine-through, is unequivocally higher than liver and/or ADC,
and is unequivocally lower than liver (Fig. 5A).20 One of the
benefits of DWI is the it has a higher detection rate of liver
tumors than conventional unenhanced MRI imaging,60 being
associated with an excellent signal-to-noise ratio with suppres-
sion of background signals from vessels and bile ducts, which
increases lesion conspicuity.61
In 2009, Zech et al.62 reported a higher sensitivity for
DWI compared to conventional MRI in the detection of HCC
in the cirrhotic liver, and Vandecaveye et al.63 concluded that
DWI provided higher sensitivity and positive predictive value
for the detection of HCC <20 mm compared to conventional
contrast-enhanced MRI. Furthermore, interestingly, there
are some evidence that indicate DWI may correlate to histo-
logical grade; as HCC progresses to poorly differentiated
HCC, there is increased cellular density, nuclear/cytoplasmic
ratio and intracellular organelles, thickened cellular plates and
shrinkage of the extra- and intra-cellular spaces,64 which may
lead to restricted diffusion and lower ADC values.65 However,
there is no consensus about the results of these techniques
so far.66–69
The main limitation of the use of DWI solely for assessing
hepatic lesions is that there is a considerable overlap between
benign and malignant lesions and normal liver tissue.70,71
In addition, it must be noticed that DWI images are very sen-
sitive to artifacts for liver motion due to respiration and arti-
facts in the left lobe derived from the heart beating.72,73
Therefore, DWI should be used in conjunction to conventional
imaging, and researchers should make every effort to
improve accuracy and reproducibility of DWI, standardizing
Fig. 4. Same patients of Figs. 1(A) and 2(B). (A) The MR T2-weighted image demonstrates that the observation is mildly hyperintense, with an inhomogeneous
structure reflecting “a mosaic architecture”, and is surrounded by a hypointense distinctive rim. (B) The MR T2-weighted image shows a focal mild hyperintensity (arrow) in a
larger isointense nodule, confirming the “nodule-in-nodule” architecture.
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imaging and technical parameters in order to increase sensi-
tivity for the detection of hepatic focal lesions.71,74–76
Importantly, it must be noted that LI-RADS endorses only
conventional DWI and not IntraVoxel Incoherent Motion (com-
monly known as IVIM) MRI, despite this method potentially
enables the estimation of microvessel perfusion without the
need for injection of intravenous contrast media.77 Several
studies have suggested that it could have a better diagnostic
performance than ADC and conventional MRI in distinguishing
high-grade HCC from low-grade HCC for liver tumors diagnos-
tic evaluation,78,79 being potentially correlated to the histolog-
ical grade of tumors.66,69,80
Iron sparing
Iron sparing refers to the lack of iron deposition in a solid
mass relative to an iron-overloaded liver or inside an inner
nodule relative to siderotic outer nodule.20 This feature
should raise concerns for premalignancy or malignancy
because it is typical of high-grade dysplastic nodules and
HCCs, which lose the ability to concentrate iron at the
same degree of functional liver parenchyma.81,82 The LI-
RADS includes this feature between those favoring malig-
nancy, but not HCC in particular, since it can be observed
in other malignancies as well, such as ICCs and benign enti-
ties like confluent fibrosis.9
Iron sparing can be detected either on CT or MRI. On CT,
the iron-sparing mass is less hyperdense than the back-
ground iron-overloaded liver, which is characterized by
greater attenuation values than normal (usually more than
75 HU on unenhanced images).9 On T2- or T2*-weighted
images on MRI, iron-sparing observations appear as hyper-
intense areas compared to the hypointense siderotic hepatic
parenchyma, since hepatic iron causes progressive signal
loss with longer echo time, whereas HCC lesions demon-
strate very little signal loss.83
The main limitation of this feature is that it can be applied
only to iron-overloaded livers with solid nodules that
Fig. 5. A 69-year-old man with hepatitis C cirrhosis, already treated for HCC in the past, who was referred for magnetic resonance imaging after the
detection of a 25-mm hypoechoic nodule in his regular ultrasound follow-up. DWI (A) and T2-weighted image (B) demonstrate the presence of a mildly hyper-
intense nodule, both with the characteristics of ancillary features favoring malignancy, but not HCC in particular. The dynamic phases show a targetoid appearance either in
the arterial phase (note the rim hyperenhancement) (C), in the portal venous phase (D) and in the hepatobiliary phase (E), meeting the criteria for LR-M. The patient
underwent a colonoscopy which found an ulcerative lesion in the left colon. A following liver biopsy confirmed that the lesion was a colon cancer metastasis.
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unequivocally have lower fractional iron content than back-
ground parenchyma.9
Corona enhancement
LI-RADS defines corona enhancement as a periobservational
enhancement in the late arterial or early portal venous phase,
with fading to isoenhancement at subsequent phases.20 This
feature is typical of hypervascular and progressed HCC,
being correlated to the modifications of venous drainage
during multistep hepatocarcinogenesis from hepatic veins to
hepatic sinusoids and then to portal veins.84 Indeed, portal
drainage vessels carry contrast agents from the tumor into
the surrounding sinusoids, resulting in corona-shaped perile-
sional enhancement few seconds after the tumor itself begins
to enhance.9 The corollary is that corona enhancement
cannot be observed in early HCC, which are drained by
hepatic veins.85
Corona enhancement is not specific for HCC, as it may be
present in hypervascular metastasis as well,9 and therefore
it is included in the LI-RADS ancillary features for malig-
nancy.20 However, it can represent a helpful tool for differ-
entiation of small hypervascular HCCs from pseudolesions,
such as arterioportal shunts, since it is always absent in the
latter.86 Furthermore, evidence suggests that large or irreg-
ular and/or distorted corona enhancement predicts micro-
vascular invasion, and therefore it can have an important
prognostic value.87,88
Ancillary features favoring HCC in particular
Intralesional fat
Intralesional fat consists of excess lipid within a mass, in whole
or in part, relative to the background liver.20 This feature can
be best detected with MRI in association with signal loss on
out-of-phase compared with in-phase T1-weighted gradient
echo sequence images. Although it is relatively uncommon
(having a sensitivity for HCC of 12–37%), this feature has a
high specificity for HCC (68–100%); hence, in a high-risk pop-
ulation, the detection of intralesional fat in a solid hepatic
nodule should raise concerns for HCC.23,55,89
Histologically, fatty metamorphosis seems to occur late
during hepatocarcinogenesis, when an early-stage HCC grad-
ually changes its blood supply from portal to arterial.90 At this
transition stage, there may be some degree of ischemia, which
could cause the fatty infiltration.90 However, the mechanism of
this transformation is not yet fully understood.90 It has been
assessed that intralesional fat is most frequently found in early
HCCs having a diameter of approximately 1.5 cm, and that its
prevalence decreases proportionally with tumor size and his-
tologic grade.90 Furthermore, it seems that intralesional fat
can have a prognostic value, since patients with fat-containing
HCCmay have a better clinical outcome than those without fat-
containing HCCs, due to longer progression of the tumor and
decreased risk of metastasis.91
Besides HCC, fatty changes can also occur in other patho-
logic conditions, such as high-grade dysplastic nodule and,
occasionally, in low-grade dysplastic nodules.86 Differential
diagnosis also includes angioleiomyolipoma and liposarcoma,
though they are unusual findings in cirrhotic livers.92 Con-
versely, this feature is extremely rare in ICCs and most meta-
stases, thereby helping differential diagnosis in indeterminate
cases.9 Interestingly, in steatohepatitic HCC (a newly described
variant of HCC, characterized by histologic features that resem-
ble those of steatohepatitis in nonneoplastic liver), the fatty
metamorphosis seems to appear in progressed forms with
advanced tumor grade as well.93
Mosaic architecture
The LI-RADS defines mosaic architecture as the presence
of randomly distributed internal nodules or compartments,
usually with different imaging features (Figs. 1 and 4A).20
This heterogeneous appearance reflects the mosaic configura-
tion observed at pathologic examination and is linked to the
simultaneous existence inside the tumor of multiple nodules,
which are featured by variable degrees of histologic differentia-
tion, fibrous septations, necrosis, hemorrhage and occasionally
copper deposition or intralesional fat.10,94 It has been demon-
strated that mosaic architecture appears in 28–63% of cases of
HCC, and is fairly typical of large tumors.95–97 Therefore, the
utility of this ancillary sign remains uncertain in the character-
ization of small HCCs, but considering its high specificity for
HCC, individuation of mosaic pattern may help differentiating
HCC from ICC.9
Interestingly, a recent retrospective study conducted on
275 nonmetastatic HCC larger than 5 cm, suggested that the
mosaic pattern may represent a prognostic factor as well,
being associated with limited liver resection efficacy.94
Nodule-in-nodule architecture
Nodule-in-nodule architecture is defined as the presence of a
smaller inner nodule within a larger outer nodule, with differ-
ent imaging features (Figs. 2C, 2D and 4B).20 Histologically,
such a condition corresponds to a developing focus of local-
ized, progressed HCC98 within a well-differentiated HCC or
dysplastic nodule, occasionally still rich in fat or iron.9,10
Thus, a nodule-in-nodule appearance may be interpreted as
a morphologic marker of the progression of dedifferentiation
of the tumor.99 By MRI observation, the inner nodule may
show other major or ancillary features for HCC, while the sur-
rounding nodule demonstrates features of benignity.100 The
presence of nodule-in-nodule appearance of HCC as a prog-
nostic indicator is not established.9
Diagnostic algorithm
In this section, we will focus on untreated observations.
When a radiologist approaches a CT or MRI liver examina-
tion, the first thing he/she is supposed to do is to verify whether
the available images are technically adequate for LI-RADS
application. If the quality of the exam is not sufficient to allow
an interpretation, the observation should be defined as LR-non-
categorizable.20 In the opposite case, the radiologist can apply
the LI-RADS algorithm, providing a categorization for each
observation detected in the liver. Indeed, it should be noted
that the LI-RADS does not assign a category to the entire
liver, but it contemplates the coexistence in the same organ
of multiple observations that can be classified differently.18
The first step is to verify whether the observation meets the
criteria of benignity. The LI-RADS defines benign entities as
solid nodules with a distinctive imaging appearance compared
to background cirrhotic nodules, with nomajor features of HCC
or any other ancillary features of malignancy. Namely, a benign
nodule is supposed to be characterized by T1 hyperintensity,
low or very high T2 signal, HBP hyper/isointensity, marked iron
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Table 4. LI-RADS tie-breaking rules for uncertain situations. From the American College of Radiology - Liver imaging reporting and data system version
(LI-RADS®) v2017
Fig. 6. LI-RADS rules to specify LR-TIV etiology (on the top). From the American College of Radiology - Liver imaging reporting and data system version (LI-RADS®)
v2017. Cirrhotic 56-year-old patient (on the bottom). The axial (A), the coronal (B, C) and the sagittal (D) computed tomography images show an infiltrating lesion of the left
lobe invading the portal vein at the bifurcation, with involvement of both the left and right portal branches. The observation was definitively a LR-TIV. Since the contiguous
lesion was >2 cm, presented a “wash-out” (major criteria), but not a clear APHE in the arterial phase (not in this box), it could be classified as an LR-4. Thus, the correct
definition in reports should be LR-TIV probably due to HCC. The lesion was biopsied and resulted in a diagnosis of HCC. The patient underwent sorafenib therapy.
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concentration or any combination of them.20 Moreover, an
observation can be classified as benign only if its size does
not increase and if its diameter does not exceed 20 mm.
Importantly, if the diameter is more than 20 mm, the obser-
vation should be categorized as LR-3.20 If the imaging features
allows a certain diagnosis of benignity, the observation should
be labelled as LR-1; otherwise, if the probability of benignity is
still high but less than 100%, the observation should be clas-
sified as LR-2. Examples of LR-1 and LR-2 entities are listed in
Table 2.
Interestingly, when the findings are suggestive of FNH or
HCA, the LI-RADS recommends to categorize the observation
as LR-3 or, with caution, as LR-2, but never as LR-1. The
rationale is that these are supposed to be diagnoses of
exclusion in high-risk patients.20 Whether the observation
does not meet the criteria for LR-1 or LR-2, the subsequent
step is to look for the presence of major criteria for HCC.
Namely, the radiologist should assess if an APHE, with the
fore-mentioned features (i.e. not rim enhancement) can be
detected. This should be the first step since, as it is shown in
Fig. 1, the LI-RADS algorithm uses the presence or the
absence of APHE to delineate two different situations: obser-
vations without APHE, which should be classified employing
the guidelines in the left part of the table; and, observations
with APHE, which need to be categorized using the right part
of the table.20 Thus, according to the size and the presence of
other major features, lesions without APHE can be labelled
just as LR-3 or LR-4, while those with APHE can range from
LR-3 to LR-5.20
Indeed, unlike other RADS systems, the LI-RADS algorithm
was conceived to define, by application of stringent diagnostic
criteria, a LR-5 category, featuring nearly 100% specificity of
HCC and eliminating the need for biopsy.19 Therefore, obser-
vations without APHE, regardless of their size, and observa-
tions less than 10 mm, despite their imaging features,
cannot be classified as LR-5, which is consistent with the
United Network for Organ Sharing requirements.19 Further-
more, LI-RADS recommends the application of major criteria
only if they can be unequivocally detected.20 Given these con-
siderations, clinicians should be conscious that a LI-RADS cat-
egory less than LR-5 does not exclude HCC.18
Interestingly, the right side of the table includes a “split”
cell, corresponding to observations with APHE, sizing of
10–19 mm, and one other major feature. These observations
can be up-graded to LR-5 only if they were reported as a
distinctive nodule on a former ultrasound examination, or
they achieve the threshold growth of $50% in <6 months; in
the first case, the lesions should be assigned to the category
LR-5us, while in second one they should be depicted as LR-5g.
In all the other instances, the observation must be classified
as LR-4.19,20
Once the evaluation of the major features is concluded and
an initial category is assigned, the radiologist can decide,
according to her/his discretion, whether to apply the ancillary
features to adjust the label, especially if she/he disposes of a
multiparametric MRI examination. The LI-RADS v2017 pro-
vides few rules for their employment (Fig. 3).20 First of all,
ancillary features do not upgrade LR-4 to the LR-5 category.
In addition, the use of ancillary features cannot allow a change
of category by more than one level, regardless of the number
of features. Eventually, if there are conflicting ancillary fea-
tures (some of them favoring benignity and some of them
favoring malignancy), the label should not be adjusted.20
The LI-RADS also provides guidelines, called “tie-breaking
rules”, to overcome the cases of indecision between two
categories generally, recommending the choice of the alter-
native which involves the higher degree of uncertainty
(Table 4).20 Figs. 1–3 present some examples of LR-4 and LR-5.
When the findings suggest malignancy, but they are not
specific for HCC, the advisable category should be LRm.
Namely, this category should include all nodular alterations
featured by a targetoid appearance (concerning either the
dynamic pattern or the morphological aspect in DWI or HBP),
infiltrative appearance, marked diffusion restriction, necrosis
or severe ischemia or other feature that in the radiologist’s
judgment suggests a nonHCC malignancy (Fig. 5).20 Once the
malignancy is assessed (LR-5 or LRm) or a HCC is highly sus-
pected (LR-4), the radiologist is supposed to verify the portal
involvement by the tumor. When an unequivocal enhancing
soft tissue is present in the vein, the report should be catego-
rized as LR-TIV and the etiology must be indicated as shown in
Fig. 6. Importantly, the assignment of this category does not
necessarily require the visualization of a parenchymal mass.20
Conclusions
The LI-RADS provides a diagnostic algorithm aimed at stand-
ardizing the interpretations and reports of liver observations
in a high-risk population for HCC, in order to optimize patient
management. This system was conceived to reduce the
indeterminacy, classifying the observations in five categories
corresponding to increasing probability of HCC on the basis of
the unequivocal presence of major and ancillary features.
Furthermore, different from other organs Reporting and Data
Systems, the LI-RADS enables the diagnosis of HCC without
the need for any further biopsy, designing a LR-5 category
featuring 100% specificity. Thus, radiologists and clinicians
must be aware that not-benign categories less than LR-5 do
not exclude the diagnosis of HCC, and that the LR-4 obser-
vation namely, just like the LR-5, may deserve a multi-
disciplinary discussion for consensus management.20
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